Treatment of cancer using antibodies to LRRC15
AssigneeBiogen Idec Inc.
InventorsWilliam Kloetzer, Karen McLachlan, Michael La Barre, Jonathon Fitchett, Robert Peach, Bill Shestowsky, Scott Glaser
Life of this patent
Estimating the term…
Loading patent…
AssigneeBiogen Idec Inc.
InventorsWilliam Kloetzer, Karen McLachlan, Michael La Barre, Jonathon Fitchett, Robert Peach, Bill Shestowsky, Scott Glaser
Estimating the term…
The present invention is directed to novel methods of treating or diagnosing a hyperproliferative disease or disorder in an patient, where the methods include administrating to the patient a binding molecule which binds to a cell surface-expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding molecule, for example an antibody or immunospecific fragment thereof, which specifically binds to the human LRRC15 protein. The present invention further provides a method of isolating and identifying cell surface expressed glycoproteins expressed in tumor or tumor associated tissues, where the method includes isolating desired glycoproteins via their affinity for specific lectins.
1-168. (canceled)
A method for treating a hyperproliferative disease or disorder in an animal, comprising administering to an animal in need of treatment a composition comprising:
A method of detecting abnormal hyperproliferative cell growth in a patient, comprising:
A method of diagnosing a hyperproliferative disease or disorder in a patient, comprising:
Dependencies are inferred from the claim text.